The Genomic Landscape of Uterine Leiomyosarcoma

Researchers at the Walter and Eliza Hall Institute of Medical Research have recently published a review article on uterine leiomyosarcoma (uLMS).

This rare and aggressive cancer arises from the smooth muscle wall of the uterus. However, the survival rate for patients with uLMS remains only at 42-76% due to delayed diagnosis and its high recurrence rate. 

A number of frequent mutations such as TP53, RB1, ATRX, PTEN, and MED12, has been identified in uLMS patients. This paper comprehensively evaluates the pre-clinical studies and clinical trials undertaken to target these mutations. This may open up new therapeutic avenues and improve outcomes for patients suffering from uLMS.